Tango Therapeutics (TNGX) Other Operating Expenses (2020)
Tango Therapeutics (TNGX) posted quarterly Other Operating Expenses of -$36.8 million for Q1 2026, up 5.9% year-over-year from -$34.7 million in Q1 2025, and up 5.9% quarter-over-quarter from -$39.1 million in Q1 2025.
Powered by 
Analysis
Tango Therapeutics (TNGX) Other Operating Expenses (2020) Analysis & Trends
Tango Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at -$36.8 million for Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Tango Therapeutics | 3.37 Bn | 2.35 Bn | - |